Pan-cancer
Cancer Type
Formalin-fixed, paraffin-embedded (FFPE) tumor tissue
Specimen Requirements
14 calendar days
Turnaround Time ¹
OncoOmicsDx™ Clinical Tumor Proteomics Test utilizes an advanced high-throughput mass spectrometry platform combined with proprietary targeted proteomics technology to perform absolute quantification of key tumor-associated proteins. Each test can simultaneously measure the expression levels of up to 30 or 72 tumor biomarker proteins, delivering high-resolution protein expression data for patients with solid tumors.
Proteomics in action – The next horizon in precision oncology for cancer treatment
30/ 72
Absolute quantification of 30 or 72 protein expression level
Certified
CAP-accredited and CLIA-certified clinical proteomics laboratory and approval from the New York State Laboratory Evaluation Program (CLEP)
Assay Introduction
Patient-specific tumor proteome for personalized cancer treatment
OncoOmicsDx™ can simultaneously analyze theexpression of 30 or 72 tumor-associated proteins, providing absolute quantification data. This high-resolution proteomic information helps predict apatient’s potential response to various therapies, including chemotherapy,targeted therapy, and antibody-drug conjugates (ADCs). It serves as a powerful tool to support clinicians in developing personalized treatment strategies,ultimately enhancing therapeutic efficacy and patient outcomes.
For example:
- Protein expression for ADCs—including antibody targets such as EGFR, HER2, HER3, FRα, and Trop2, as well as payload biomarkers for sensitivity (TOPO1) and resistance (TUBB3)—can guide ADCselection and predict treatment response.
- HER2 protein expression serves as acritical biomarker for selecting anti-HER2 therapies such as trastuzumab.
- TOPO1 expression can predict theresponse to topoisomerase I inhibitors like irinotecan.
- TUBB3 levels help assess the potential efficacy of certain microtubule-inhibiting chemotherapeutic agents, such as taxanes.
- MGMT (O6-methylguanine-DNAmethyltransferase) expression is closely associated with response totemozolomide, making it an important indicator for evaluating temozolomide treatment in patients with glioblastoma multiforme (GBM).
Comprehensive Proteomics Database
We hold over 40 global patents and havetested more than 10,000 clinical samples. Through this, we have built aclinically validated mass spectrometry-based proteomic database focused on 72cancer-related proteins. Through absolute quantification of multiple targetproteins using proteomics analysis, OncoOmicsDx™ enables a more comprehensive understanding of tumor cell protein expression profiles in clinical practice.
Certified U.S.-based Clinical Proteomics Laboratory
The U.S.-based Clinical Proteomics Laboratory is certified by CAP, CLIA, and the New York State Department ofHealth (NYSDOH), meeting the highest international standards for clinical quality and regulatory compliance. All testing procedures and biomarker analysesundergo rigorous validation in accordance with CAP/CLIA/NYSDOH requirements, ensuring the accuracy, reliability, and clinical applicability of the results.
Based on a high-resolution massspectrometry platform, our laboratory performs absolute quantification of 72clinically validated tumor-associated proteins with established clinicalcut-off values. This provides a scientific and reliable foundation for medicaldecision-making, supporting the implementation of high-quality precisionmedicine.
Rapid Turnaround with clinical relevance
Results delivered within 14 calendar days,meeting clinical timelines (counting from the receipt of a qualified sample atthe laboratory).
Expert Report Consultation Service
One-on-one consultation for personalized testreports, providing a detailed explanation of the analysis results.
Expert Team for Precise Interpretation
Our team consists of specialists in tumorbiology, medicine, molecular biology, cell biology, immunology, bioinformatics,big data analytics, and pharmacology. By integrating bioinformatics databases,we deliver in-depth interpretation of protein expression data, providing comprehensive analysis and treatment recommendations.
Summary
OncoOmicsDxTM Assay – Thetechnology
Comprehensive personalized molecularsolution to inform cancer care
Compared to traditional immunohisto chemistry (IHC), OncoOmicsDx™ leverages mass spectrometry (MS) combined with targeted proteomics technology to deliver more accurate and consistent absolute quantification data. IHC is a semi-quantitative methodprone to variability due to subjective interpretation, sample quality, andstaining conditions, and is typically limited to analyzing one or a few targetsat a time. In contrast, mass spectrometry enables simultaneous analysis ofdozens of protein biomarkers, improving diagnostic efficiency and significantly increasing data density and clinical relevance—providing robust support forprecision medicine.
The OncoOmicsDx™ testing platform utilizesa high-resolution mass spectrometer in combination with Multiple Reaction Monitoring (MRM-MS) techniques toquantitatively analyze target proteins.
During the analytical process, specificmass spectrometry transitions are designed for each peptide fragmentcorresponding to the target protein. These are paired with high-purity stableisotope-labeled internal standards to establish dedicated chromatographicseparation and signal acquisition protocols. Absolute quantification is achievedby comparing the area ratios of chromatographic curves between the analyte andits internal standard.
This approach offers the following technical advantages:
- High Sensitivity and Selectivity: The Multiple Reaction Monitoring mass spectrometry (MRM-MS) technique enables accurate detection of low-abundance target proteins in complex biological samples,significantly reducing interference from non-specific background signals.
- High Reproducibility and Quantitative Accuracy: Internal standards are used for calibration, enhancing dataconsistency across different samples and analytical batches.
- High-Throughput Multiplex DetectionCapability: With Triple Quadrupole Mass Spectrometry (QQQ-MS), theplatform can monitor dozens of proteins, enabling efficient and precise multiplex quantitative analysis for targeted protein expressions.
Eligible patient characteristics
- Cancer patients who are facing complex treatment decisions
- Individuals seeking to implement precision strategies, using protein expression analysis to guidethe selection of chemotherapy, targeted therapy, and ADC.
- Patients exploring options beyond standard treatments, such as those who have not responded to existing therapies or cannot tolerate them.
Use cases:
- Evaluation of protein biomarkers associated with chemotherapy
- Evaluation of protein biomarkers related to targeted therapy and immunotherapy
- Assessment of protein markers relevant to antibody-drug conjugates (ADCs)
- Tumor prognosis assessment
- Evaluation for other treatment options
Technical Specifications
MRM-MS Quantification Method
Multiple Reaction Monitoring Mass Spectrometry (MRM-MS) Detection Technique
Laser Microdissection Sampling Method
Using specialized DIRECTOR® slides, tumor cells are precisely isolated through lasermicrodissection
Absolute Protein Quantification
30or 72 target proteins quantified
Documentation
Disclaimers / Footnotes
- Turnaround time starts from the date of receipt of approved samples at our CAP-accredited laboratory.
- Please refer to our specimen instructions.
